Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

"Circulating Fetal DNA, Pregnancy And Immune Diseases" (AFFEPI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04155086
Recruitment Status : Not yet recruiting
First Posted : November 7, 2019
Last Update Posted : November 7, 2019
Sponsor:
Collaborator:
CERBA laboratory
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

In the plasma of any pregnant patient circulates DNA (also called circulating free DNA). The vast majority of this circulating free DNA is of maternal origin and about 10% is of fetal origin (fetal circulating free DNA). This percentage of fetal circulating free DNA (corresponding to the fetal fraction) increases with gestation.

The pathophysiological hypothesis of this research is that there is a change in the fetal fraction (FF) of fetal circulating free DNA in patients with autoimmune disease (AID). The underlying mechanism would be a massive release of maternal cfDNA responsible for a dilution of fetal cfDNA. This dilution of fetal cfDNA would result in a decrease in the estimate of the foetal fraction of circulating free DNA. However, when the foetal fraction of circulating free DNA is insufficient (4% most often), screening for Trisomy 21 (T21) by fetal circulating free DNA becomes uninterpretable (NC for "non-contributory" result), and cannot be used to assess the risk of T21. In this case, the dose of fetal circulating free DNA can be performed again after 15 days, as the amount of fetal circulating free DNA increases with gestation. In a small number of cases the result will remain NC.

As tests using DNA are becoming more widespread, it is important to prospectively evaluate the results of these tests in the population of patients with AID, which represents about 3 to 5% of pregnant women.


Condition or disease Intervention/treatment Phase
Autoimmune Diseases Pregnancy Biological: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis Not Applicable

Detailed Description:

Circulating fetal DNA (cfDNA) in maternal blood is now routinely used for prenatal screening for Down syndrome 21 (T21). In about 1% of cases, the test result is not contributory (NC). The investigator's team recently found, in a retrospective study, an association between the existence of an autoimmune disease (AID) and a high risk of NC. However, this was only a subgroup analysis, requiring confirmation by a dedicated study. Tests using deoxyribonucleic Care (dNCare) are becoming more widespread, so it is important to prospectively evaluate the results of these tests in the population of patients with AID, which represents about 3 to 5% of pregnant women.

The main objective of this study is to compare the rate of NC in a population of patients with DIA to that of a population of patients without MAI when screened for T21 by the cfDNA study in the first trimester of pregnancy.

The secondary objectives are :

  • To assess the performance of fetal cfDNA for T21 screening in the population of PATIENTS with AID and to compare them with performance in the non-auto immune disease population.
  • To assess the performance of the combined first trimester screening for T21 screening and compare it with those of fetal cfDNA in the population of patients with AID.
  • In patients with an NC result, analysis of the distribution of fetal fractions according to the presence and severity of maternal autoimmune pathologies. The distribution will be compared to that of the control population.
  • To assess the association between fetal fraction and the occurrence of vascular complications of pregnancy in both groups with and without auto immune disease.

AFFEPI is a prospective multicenter, interventional, exposed/non-exposed cohort study

There are two group :

Exposed group: Any patient with a auto immune disease followed at one of the 14 centres who wants to be screened for T21.

Unexposed group: Patients who do not carry an auto immune disease identified at the interview (no history of auto immune disease; no symptoms suggestive of a auto immune disease).


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: "Fetal Aneuploidy Screening (21, 18 and 13) by Analysis of Circulating Fetal DNA in a Population of Pregnant Patients With Autoimmune Diseases"
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Exposed group (patient with an autoimmunise disease)
Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
 Biological: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Non Exposed group (patient without an autoimmunise disease) Biological: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The number of inconclusive results of the free circulating fetal DNA test [ Time Frame: maximum 15 days after inclusion if the result of the initial analysis is inconclusive. Or maximum 30 days after inclusion if the analysis is realized a second time ]
    The detection of the risk of fetal trisomy 21 by 2 blood tests : free circulating analysis fetal DNA and first trimester serum screening. A result of the free fetal DNA circulant test is rendered as inconclusive when the fetal fraction is strictly less than 4% or the result of the z-scores is not interpretable


Secondary Outcome Measures :
  1. Performance (ability to detect the risk) of fetal DNA for T21 screening in the auto immune disease population. and To compare them with the non-auto immune disease population. [ Time Frame: maximum 15 days after inclusion if the result of the initial analysis is inconclusive, or maximum 30 days after inclusion if the analysis is realized a second time ]
    The results of free circulating fetal DNA analysis and first trimester serum screening for T21 screening

  2. Performance (ability to detect the risk) of the combined first trimester serum screening for T21 screening and compare it with those of fetal DNA in auto immune disease population. [ Time Frame: maximum 15 days after inclusion if the result of the initial analysis is inconclusive, or maximum 30 days after inclusion if the analysis is realized a second time ]
    The results of free circulating fetal DNA analysis and first trimester serum screening for T21 screening

  3. Distribution of fetal fractions according to the presence and severity of maternal autoimmune pathology [ Time Frame: maximum 15 days after inclusion if the result of the initial analysis is inconclusive, or maximum 30 days after inclusion if the analysis is realized a second time ]
    Distribution of the results of free circulating fetal DNA analysis and first trimester serum screening for T21 screening in the group of patient with autoimmune disease

  4. Association between fetal fraction and the occurrence of vascular complications of pregnancy in both groups with and without auto immune disease. [ Time Frame: maximum 15 days after inclusion if the result of the initial analysis is inconclusive, or after inclusion if the analysis is realized a second time ]
    The detection of the risk of fetal trisomy 21 : Free circulating fetal DNA analysis and first trimester serum screening


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   pregnant population
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients in the exposed group:

  • Single-fetal pregnancy with a term between 11 and 13-6 weeks of amenorrhea (SA) from spontaneous pregnancy or by medical assistance to procreation.
  • Age ≥ 18 years
  • Affiliated with a social security or beneficiary scheme
  • Desire for natal screening of T21, not yet realized
  • Patient with a condition on the following list: [see Chapter 7.2]

Patients in the unexposed group:

  • Single-fetal pregnancy with a term between 11 and 13-6 weeks of amenorrhea (SA) from spontaneous pregnancy or by medical assistance to procreation.
  • Age ≥ 18 years
  • Affiliated with a social security or beneficiary scheme
  • Desire for natal screening of T21, not yet realized
  • No pathology that meets the list mentioned in the above section
  • Clinically asymptomatic patient with no clinical symptoms suggestive of AID: arthralgias, skin or mucous disease, dry syndrome, Raynaud syndrome, purpura.
  • Patient respecting frequency pairing

Exclusion Criteria:

  • BMI > 35 kg/cm2
  • Multiple pregnancy
  • No first trimester ultrasound (between 11 and 13-6 SA)
  • Screening for unwanted T21
  • Patients already included in an interventional research protocol
  • Morphological abnormalities on first trimester ultrasound and/or nucal clarity - 3.5mm
  • Patient under the protection of justice
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04155086


Locations
Layout table for location information
France
Hôpital Antoine Béclère Not yet recruiting
Clamart, Ile De France, France
Contact: Alexandre Vivanti    01.45.37.44.41    alexandre.vivanti@aphp.fr   
Contact: Alaxandra Benachi    01.45.37.44.76    alexandra.benachi@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
CERBA laboratory
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04155086     History of Changes
Other Study ID Numbers: APHP180669
2019-A01827-50 ( Other Identifier: IDRCB number )
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
autoimmune disease
pregnancy
free fetal DNA circulant
Additional relevant MeSH terms:
Layout table for MeSH terms
Autoimmune Diseases
Immune System Diseases